Abstract
Altered systemic iron metabolism is a key element of uremia, and functional iron deficiency mainly related to subclinical inflammation makes it difficult to maintain proper control of anemia in chronic hemodialysis patients (CHD). In the last decade, the hepatic hormone hepcidin has been progressively recognized as the master regulator of circulating iron levels through the modulation of cellular iron fluxes in response to iron stores, as well as to erythroid and inflammatory stimuli. Hepcidin is cleared by the kidney and progression of renal disease has been associated to increased serum hepcidin levels. This, in turn, reduces iron availability for erythropoiesis, suggesting anti-hepcidin strategies for improving anemia control. Moreover, hepcidin has been recently implicated in the pathogenesis of long-term complications of dialysis, like accelerated atherosclerosis. Initial studies almost invariably reported a sustained increase of serum hepcidin in chronic hemodialysis patients. Noteworthy, such studies included relatively few patients and controls that were poorly matched for major determinants of serum hepcidin at population level, i.e., age and gender. More recent data based on accurately matched larger series challenge the view that hepcidin is intrinsically increased in hemodialysis patients, showing a marked inter- and intra-individual variability of hormone levels. Here we take a critical look to the data published so far on hepcidin levels in CHD, analyze the reasons underlying the discrepancies in available studies and the hepcidin variability in CHD, and point out the need for further studies in large series of well-characterized CHD patients and controls.
Acknowledgments
We thank Silvia Fargion, Daniela Toniolo, and particularly Clara Camaschella for helpful comments and suggestions. This work is partially supported by the Italian Ministry of University and Research (grant no. 200989KXFN) and by Fondazione Cariverona, project Verona Nanomedicine Initiative to DG.
Conflict of interest statement
Authors’ conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article. Research funding played no role in thestudy design; in the collection, analysis, and interpretationof data; in the writing of the report; or in the decision tosubmit the report for publication.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
References
1. Lankhorst CE, Wish JB. Anemia in renal disease: diagnosis and management. Blood Rev 2010;24:39–47.10.1016/j.blre.2009.09.001Search in Google Scholar
2. Gunnell J, Yeun JY, Depner TA, Kaysen GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 1999;33:63–72.10.1016/S0272-6386(99)70259-3Search in Google Scholar
3. Kalantar-Zadeh K, McAllister CJ, Lehn RS, Liu E, Kopple JD. A low serum iron level is a predictor of poor outcome in hemodialysis patients. Am J Kidney Dis 2004;43:671–84.10.1053/j.ajkd.2003.12.029Search in Google Scholar PubMed
4. Ganz T. Hepcidin and iron regulation, 10 years later. Blood 2011;117:4425–33.10.1182/blood-2011-01-258467Search in Google Scholar PubMed PubMed Central
5. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090–3.10.1126/science.1104742Search in Google Scholar PubMed
6. Ganz T. Macrophages and systemic iron homeostasis. J Innate Immun 2012;4:446–53.10.1159/000336423Search in Google Scholar PubMed PubMed Central
7. Muckenthaler MU. Fine tuning of hepcidin expression by positive and negative regulators. Cell Metab 2008;8:1–3.10.1016/j.cmet.2008.06.009Search in Google Scholar PubMed
8. Canavesi E, Valenti L. Modulation of iron metabolism and hepcidin release by HFE mutations in chronic hemodialysis patients: pathophysiological and therapeutic implications. In: Penido MG, editor. Hemodialysis: Intech Open Access Publisher, 2011:139–72.Search in Google Scholar
9. Zaritsky J, Young B, Wang HJ, Westerman M, Olbina G, Nemeth E, et al. Hepcidin-a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 2009;4:1051–6.10.2215/CJN.05931108Search in Google Scholar PubMed PubMed Central
10. Tomosugi N, Kawabata H, Wakatabe R, Higuchi M, Yamaya H, Umehara H, et al. Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System. Blood 2006;108:1381–7.10.1182/blood-2005-10-4043Search in Google Scholar PubMed
11. Zaritsky J, Young B, Gales B, Wang HJ, Rastogi A, Westerman M, et al. Reduction of serum hepcidin by hemodialysis in pediatric and adult patients. Clin J Am Soc Nephrol 2010;5:1010–4.10.2215/CJN.08161109Search in Google Scholar PubMed PubMed Central
12. Campostrini N, Castagna A, Zaninotto F, Bedogna V, Tessitore N, Poli A, et al. Evaluation of hepcidin isoforms in hemodialysis patients by a proteomic approach based on SELDI-TOF MS. J Biomed Biotechnol 2010;2010:329646.10.1155/2010/329646Search in Google Scholar PubMed PubMed Central
13. Weiss G, Theurl I, Eder S, Koppelstaetter C, Kurz K, Sonnweber T, et al. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy. Eur J Clin Invest 2009;39:883–90.10.1111/j.1365-2362.2009.02182.xSearch in Google Scholar PubMed
14. Valenti L, Girelli D, Valenti GF, Castagna A, Como G, Campostrini N, et al. HFE mutations modulate the effect of iron on serum hepcidin-25 in chronic hemodialysis patients. Clin J Am Soc Nephrol 2009;4:1331–7.10.2215/CJN.01370209Search in Google Scholar PubMed PubMed Central
15. Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 2009;75:976–81.10.1038/ki.2009.21Search in Google Scholar PubMed
16. Peters HP, Laarakkers CM, Swinkels DW, Wetzels JF. Serum hepcidin-25 levels in patients with chronic kidney disease are independent of glomerular filtration rate. Nephrol Dial Transplant 2010;25:848–53.10.1093/ndt/gfp546Search in Google Scholar PubMed
17. Tessitore N, Girelli D, Campostrini N, Bedogna V, Solero P, Castagna A, et al. Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents. Nephrol Dial Transplant 2010;25:3996–4002.10.1093/ndt/gfq321Search in Google Scholar PubMed
18. Ghoti H, Rachmilewitz EA, Simon-Lopez R, Gaber R, Katzir Z, Konen E, et al. Evidence for tissue iron overload in long-term hemodialysis patients and the impact of withdrawing parenteral iron. Eur J Haematol 2012;89:87–93.10.1111/j.1600-0609.2012.01783.xSearch in Google Scholar PubMed
19. Costa E, Swinkels DW, Laarakkers CM, Rocha-Pereira P, Rocha S, Reis F, et al. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in haemodialysis patients. Acta Haematol 2009;122:226–9.10.1159/000253590Search in Google Scholar PubMed
20. Kuragano T, Shimonaka Y, Kida A, Furuta M, Nanami M, Otaki Y, et al. Determinants of hepcidin in patients on maintenance hemodialysis: role of inflammation. Am J Nephrol 2010;31: 534–40.10.1159/000312381Search in Google Scholar PubMed
21. Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol 2012;23:1631–4.10.1681/ASN.2011111078Search in Google Scholar PubMed PubMed Central
22. Shoji S, Inaba M, Tomosugi N, Okuno S, Ichii M, Yamakawa T, et al. Greater potency of darbepoetin-alpha than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients. Eur J Haematol 2013;90:237–44.10.1111/ejh.12067Search in Google Scholar PubMed
23. Liu Q, Davidoff O, Niss K, Haase VH. Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. J Clin Invest 2012;122:4635–44.10.1172/JCI63924Search in Google Scholar PubMed PubMed Central
24. Pelusi S, Girelli D, Rametta R, Campostrini N, Alfieri C, Traglia M, et al. The A736V TMPRSS6 polymorphism influences hepcidin and iron metabolism in chronic hemodialysis patients: TMPRSS6 and hepcidin in hemodialysis. BMC Nephrol 2013;14:48.10.1186/1471-2369-14-48Search in Google Scholar PubMed PubMed Central
25. Castagna A, Campostrini N, Zaninotto F, Girelli D. Hepcidin assay in serum by SELDI-TOF-MS and other approaches. J Proteomics 2010;73:527–36.10.1016/j.jprot.2009.08.003Search in Google Scholar PubMed
26. Kroot J, Laarakkers C, Geurts-Moespot AJ, Grebenchtchikov N, Pickkers P, van Ede AE, et al. Immunochemical and mass spectrometry-based serum hepcidin assays for iron metabolism disorders. Clin Chem 2010;56:1570–9.10.1373/clinchem.2010.149187Search in Google Scholar PubMed
27. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood 2008;112:4292–7.10.1182/blood-2008-02-139915Search in Google Scholar PubMed
28. Campostrini N, Traglia M, Martinelli N, Corbella M, Cocca M, Manna D, et al. Serum levels of the hepcidin-20 isoform in a large general population: The Val Borbera study. J Proteomics 2012;76 Spec No.:28–35.10.1016/j.jprot.2012.08.006Search in Google Scholar PubMed PubMed Central
29. Nemeth E, Preza GC, Jung CL, Kaplan J, Waring AJ, Ganz T. The N-terminus of hepcidin is essential for its interaction with ferroportin: structure-function study. Blood 2006;107:328–33.10.1182/blood-2005-05-2049Search in Google Scholar PubMed PubMed Central
30. Swinkels DW, Girelli D, Laarakkers C, Kroot J, Campostrini N, Kemna EH, et al. Advances in quantitative hepcidin measurements by time-of-flight mass spectrometry. PLoS ONE 2008;3:e2706.10.1371/journal.pone.0002706Search in Google Scholar PubMed PubMed Central
31. Traglia M, Girelli D, Biino G, Campostrini N, Corbella M, Sala C, et al. Association of HFE and TMPRSS6 genetic variants with iron and erythrocyte parameters is only in part dependent on serum hepcidin concentrations. J Med Genet 2011;48:629–34.10.1136/jmedgenet-2011-100061Search in Google Scholar PubMed
32. Galesloot TE, Vermeulen SH, Geurts-Moespot AJ, Klaver SM, Kroot JJ, van Tienoven D, et al. Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood 2011;117:e218–25.10.1182/blood-2011-02-337907Search in Google Scholar PubMed
33. Peters HP, Rumjon A, Bansal SS, Laarakkers CM, van den Brand JA, Sarafidis P, et al. Intra-individual variability of serum hepcidin-25 in haemodialysis patients using mass spectrometry and ELISA. Nephrol Dial Transplant 2012;27:3923–9.10.1093/ndt/gfs164Search in Google Scholar PubMed
34. van der Weerd NC, Grooteman MP, Bots ML, van den Dorpel MA, den Hoedt CH, Mazairac AH, et al. Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents. PLoS One 2012;7:e39783.10.1371/journal.pone.0039783Search in Google Scholar PubMed PubMed Central
35. Stefansson BV, Abramson M, Nilsson U, Haraldsson B. Hemodiafiltration improves plasma 25-hepcidin levels: a prospective, randomized, blinded, cross-over study comparing hemodialysis and hemodiafiltration. Nephron Extra 2012;2:55–65.10.1159/000336482Search in Google Scholar PubMed PubMed Central
36. Rostoker G, Griuncelli M, Loridon C, Couprie R, Benmaadi A, Bounhiol C, et al. Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study. Am J Med 2012;125:991–9 e1.10.1016/j.amjmed.2012.01.015Search in Google Scholar PubMed
37. Saeed O, Otsuka F, Polavarapu R, Karmali V, Weiss D, Davis T, et al. Pharmacological suppression of hepcidin increases macrophage cholesterol efflux and reduces foam cell formation and atherosclerosis. Arterioscler Thromb Vasc Biol 2012;32:299–307.10.1161/ATVBAHA.111.240101Search in Google Scholar PubMed PubMed Central
38. Valenti L, Dongiovanni P, Motta BM, Swinkels DW, Bonara P, Rametta R, et al. Serum hepcidin and macrophage iron correlate with MCP-1 release and vascular damage in patients with metabolic syndrome alterations. Arterioscler Thromb Vasc Biol 2011;31:683–90.10.1161/ATVBAHA.110.214858Search in Google Scholar PubMed
39. Kuragano T, Itoh K, Shimonaka Y, Kida A, Furuta M, Kitamura R, et al. Hepcidin as well as TNF-{alpha} are significant predictors of arterial stiffness in patients on maintenance hemodialysis. Nephrol Dial Transplant 2011;26:2663–7.10.1093/ndt/gfq760Search in Google Scholar PubMed
40. van der Weerd NC, Grooteman MP, Bots ML, van den Dorpel MA, den Hoedt CH, Mazairac AH, et al. Hepcidin-25 is related to cardiovascular events in chronic haemodialysis patients. Nephrol Dial Transplant 2012 Nov 19. [Epub ahead of print].10.1159/000338919Search in Google Scholar PubMed
©2014 by Walter de Gruyter Berlin/Boston
